bendamustine

In younger, fit patients, first-line therapy traditionally involves dose-intensified chemoimmunotherapy with high-dose cytarabine and autologous stem-cell transplantation (ASCT). The incorporation of Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib, into induction regimens has improved survival outcomes, with emerging evidence that may limit the use of ASCT to high-risk subsets...In older or transplant-ineligible patients, bendamustine-rituximab remains a backbone therapy, with chemotherapy-free combinations incorporating BTKi, BCL2 inhibitors, and anti-CD20 antibodies offering effective, well-tolerated alternatives...Ongoing trials are evaluating optimal sequencing and combination strategies to improve outcomes, particularly in high-risk and cBTKi-exposed patients. Overall, modern MCL management emphasizes individualized therapy based on biological risk, functional status, and treatment tolerability, with novel targeted and cellular approaches reshaping the frontline and relapsed treatment landscape.

P2, N=49, Recruiting, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Recruiting

P2, N=213, Recruiting, Miltenyi Biomedicine GmbH | Active, not recruiting --> Recruiting | N=45 --> 213

Patients without high-risk features (high simplified MIPI, high Ki-67, blastoid/pleomorphic morphology, TP53 mutation, or complex karyotype) had more favorable survival outcomes. These results suggest that sequential treatment with 1 L BR and 2 L BTKi remains reasonable for select patients with MCL, particularly those without high-risk features.

P3, N=86, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025

P1/2, N=50, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting

P2, N=25, Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (the First Affiliated Hospital wi

Compared with standard HDM, the BBM-protocol in ASCT2 was associated with a smaller decline in progression-free survival relative to the ASCT1, and a consistent trend toward higher effectiveness across other measures. These findings suggest that BBM may help preserve efficacy in the setting of repeated transplantation and underscore the need for larger prospective studies to confirm these results.

P1, N=36, Completed, Otsuka Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jan 2026

Post-CAR-T salvage therapy consisted of heterogeneous regimens, most commonly polatuzumab-bendamustine-rituximab and CD20 × CD3 bispecific antibody monotherapy. Response rates and short-term survival varied across approaches, with bispecific antibody monotherapy having the highest ORR (65%) and favorable 1-year outcomes (OS 56%; EFS 43%). In this contemporary multicenter cohort, salvage therapy after CAR-T failure achieved objective but often short-lived responses, with outcomes driven by relapse timing after CAR-T infusion rather than the line of prior CAR-T therapy, supporting individualized treatment selection in this high-risk setting.

The patient was treated with six cycles of rituximab-bendamustine, resulting in complete regression of the nasopharyngeal mass and reduction in splenomegaly, with minimal residual lymphadenopathy and good clinical and biological tolerance. This case highlights the importance of considering CLL in the differential diagnosis of nasopharyngeal masses and emphasizes the role of combined imaging, histology, and immunophenotyping in establishing an accurate diagnosis and guiding appropriate management.